Breaking News, Collaborations & Alliances

Paladin, Apeiron in Neuroblastoma Pact

Paladin granted rights to market APN311 in Canada and Africa

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Paladin Labs, Inc. has entered into an exclusive license agreement with Apeiron Biologics for APN311, an antibody-based immunotherapy for children with high-risk neuroblastoma. Paladin has been granted the exclusive rights to market and sell APN311 in Canada and Sub-Saharan Africa. Further details or financial terms were not disclosed.   APN311 is a monoclonal chimeric antibody produced in CHO cells targeting the GD2 antigen on neuroblastoma cells and is currently in Phase III development in Eur...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters